<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002138'>Subarachnoid hemorrhage</z:hpo> (SAH), <z:hpo ids='HP_0002383'>encephalitis</z:hpo>, <z:hpo ids='HP_0001287'>meningitis</z:hpo>, and <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> sometimes lead to cerebral <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">angiopathy</z:e>, characterized specifically by narrowing of vessels, morphological changes in the structure of vessel walls, and a concomitant decrease in cerebral blood flow </plain></SENT>
<SENT sid="1" pm="."><plain>Many patients also develop delayed ischemic neurological deficits </plain></SENT>
<SENT sid="2" pm="."><plain>Thus, preventing vascular reactions is of paramount importance in treating SAH </plain></SENT>
<SENT sid="3" pm="."><plain>Although <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> has some relationship with the inflammatory reaction of major cerebral vessels against the autologous blood, and many trials have attempted to prevent <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">angiopathy</z:e> after SAH, an effective treatment has not yet been established </plain></SENT>
<SENT sid="4" pm="."><plain>The purpose of this article is to evaluate the preventive effect of nuclear factor KB (NF-kappaB) decoy oligo-DNA after SAH; since NF-kappaB is closely related to <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>In the rabbit <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">angiopathy</z:e> model after SAH, we evaluated the effectiveness of the decoy oligo-DNA using the angiographic (digital subtraction angiography) and histological (<z:chebi fb="1" ids="51686">hematoxylin</z:chebi>-eosin and Masson's trichrome staining) methods </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, a gel-shift assay for NF-kappaB was also performed in order to evaluate the activity of NF-kappaB </plain></SENT>
<SENT sid="7" pm="."><plain>We describe a new concept for treating cerebral <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">angiopathy</z:e> after SAH and for successfully inhibiting <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> and morphological changes in vessel walls in a rabbit model </plain></SENT>
<SENT sid="8" pm="."><plain>In this treatment, we used synthetic double-strand oligo-DNA with a high affinity for transcription factor NF-kappaB, and cationic liposome complex administered through the cerebrospinal fluid </plain></SENT>
</text></document>